The DOI matches its Crossref record; 284 of the 284 references it cites were found in a registry or an index.
50 years of hurdles and hope in anxiolytic drug discovery
Open accessAbstract
Anxiety disorders are the most prevalent group of psychiatric diseases, and have high personal and societal costs. The search for novel pharmacological treatments for these conditions is driven by the growing medical need to improve on the effectiveness and the side effect profile of existing drugs. A huge volume of data has been generated by anxiolytic drug discovery studies, which has led to the progression of numerous new molecules into clinical trials. However, the clinical outcome of these efforts has been disappointing, as promising results with novel agents in rodent studies have very rarely translated into effectiveness in humans. Here, we analyse the major trends from preclinical studies over the past 50 years conducted in the search for new drugs beyond those that target the prototypical anxiety-associated GABA (γ-aminobutyric acid)–benzodiazepine system, which have focused most intensively on the serotonin, neuropeptide, glutamate and endocannabinoid systems. We highlight various key issues that may have hampered progress in the field, and offer recommendations for how anxiolytic drug discovery can be more effective in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Lesch, K.-P., Bengel, D., Heils, A., Sabol, S. Z., Greenberg, B. D., Petri, S., Benjamin, J., Müller, C. R., Hamer, D. H., & Murphy, D. L. (1996) · Science · doi:10.1126/science.274.5292.1527 · Cited by 5,162
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965
VALE, W., SPIESS, J., RIVIER, C., & RIVIER, J. (1982) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198205000-00013 · Cited by 3,904
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754
The use of a plus-maze to measure anxiety in the mouse
Lister, R. (1987) · Psychopharmacology · doi:10.1007/bf00177912 · Cited by 2,609
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
Cited by
Using Neuroscience to Help Understand Fear and Anxiety: A Two-System Framework
LeDoux, J. E., & Pine, D. S. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16030353 · Cited by 1,035
Craske, M. G., Stein, M. B., Eley, T. C., Milad, M. R., Holmes, A., Rapee, R. M., & Wittchen, H.-U. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.24 · Cited by 652
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Meningeal γδ T cells regulate anxiety-like behavior via IL-17a signaling in neurons
Alves de Lima, K., Rustenhoven, J., Da Mesquita, S., Wall, M., Salvador, A. F., Smirnov, I., Martelossi Cebinelli, G., Mamuladze, T., Baker, W., Papadopoulos, Z., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0776-4 · Cited by 416
Singewald, N., Schmuckermair, C., Whittle, N., Holmes, A., & Ressler, K. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.004 · Cited by 390
“Various neuropeptides and their corresponding receptors are localized in brain regionsmediating emotional behavior and stress response and have been considered as potential anxiolytic drug targets (Bowers et al., 2012; Ebner et al., 2009; Griebel & Holmes, 2013).”
BackgroundSelf-citationThe Roles of Serotonin in Neuropsychiatric Disorders
Pourhamzeh, M., Moravej, F. G., Arabi, M., Shahriari, E., Mehrabi, S., Ward, R., Ahadi, R., & Joghataei, M. T. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01064-9 · Cited by 366
Fontana, B. D., Mezzomo, N. J., Kalueff, A. V., & Rosemberg, D. B. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.004 · Cited by 272
Contributions of the central extended amygdala to fear and anxiety
Shackman, A. J., & Fox, A. S. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0982-16.2016 · Cited by 269
The subjective experience of emotion: a fearful view
LeDoux, J. E., & Hofmann, S. G. (2018) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2017.09.011 · Cited by 268
Comparative Analyses of Zebrafish Anxiety-Like Behavior Using Conflict-Based Novelty Tests
Kysil, E. V., Meshalkina, D. A., Frick, E. E., Echevarria, D. J., Rosemberg, D. B., Maximino, C., Lima, M. G., Abreu, M. S., Giacomini, A. C., Barcellos, L. J. G., et al. (2017) · Zebrafish · doi:10.1089/zeb.2016.1415 · Cited by 254
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
The endocannabinoid system as a target for novel anxiolytic drugs
Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.033 · Cited by 233
Self-citationDeidda, G., Bozarth, I. F., & Cancedda, L. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00119 · Cited by 192
Don’t stress about CRF: assessing the translational failures of CRF1antagonists
Spierling, S. R., & Zorrilla, E. P. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4556-2 · Cited by 170
Bluett, R. J., Gamble-George, J. C., Hermanson, D. J., Hartley, N. D., Marnett, L. J., & Patel, S. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.53 · Cited by 157
Neuropeptide and small transmitter coexistence: Fundamental studies and relevance to mental illness
Hökfelt, T., Barde, S., Xu, Z.-Q. D., Kuteeva, E., Rüegg, J., Le Maitre, E., Risling, M., Kehr, J., Ihnatko, R., Theodorsson, E., et al. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00106 · Cited by 139
Ancient anxiety pathways influence drosophila defense behaviors
Mohammad, F., Aryal, S., Ho, J., Stewart, J. C., Norman, N. A., Tan, T. L., Eisaka, A., & Claridge-Chang, A. (2016) · Current Biology · doi:10.1016/j.cub.2016.02.031 · Cited by 130
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Linking emotional valence and anxiety in a mouse insula-amygdala circuit
Nicolas, C., Ju, A., Wu, Y., Eldirdiri, H., Delcasso, S., Couderc, Y., Fornari, C., Mitra, A., Supiot, L., Vérité, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40517-1 · Cited by 107
Belzung, C. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.342 · Cited by 106
A randomized dose-ranging study of neuropeptide Y in patients with posttraumatic stress disorder
Sayed, S., Van Dam, N. T., Horn, S. R., Kautz, M. M., Parides, M., Costi, S., Collins, K. A., Iacoviello, B., Iosifescu, D. V., Mathé, A. A., et al. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx109 · Cited by 79
Masneuf, S., Lowery-Gionta, E., Colacicco, G., Pleil, K. E., Li, C., Crowley, N., Flynn, S., Holmes, A., & Kash, T. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.04.015 · Cited by 69
Self-citationCyclooxygenase-2 inhibition reduces stress-induced affective pathology
Gamble-George, J. C., Baldi, R., Halladay, L., Kocharian, A., Hartley, N., Silva, C. G., Roberts, H., Haymer, A., Marnett, L. J., Holmes, A., et al. (2016) · eLife · doi:10.7554/elife.14137 · Cited by 55
Self-citationThinking small: towards microRNA-based therapeutics for anxiety disorders
Scott, K. A., Hoban, A. E., Clarke, G., Moloney, G. M., Dinan, T. G., & Cryan, J. F. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.997873 · Cited by 52
Fernandes, L. M. P., Cartágenes, S. C., Barros, M. A., Carvalheiro, T. C. V. S., Castro, N. C. F., Schamne, M. G., Lima, R. R., Prediger, R. D., Monteiro, M. C., Fontes-Júnior, E. A., et al. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.05.007 · Cited by 46
Identification of a novel gene regulating amygdala-mediated fear extinction
Gunduz-Cinar, O., Brockway, E., Lederle, L., Wilcox, T., Halladay, L. R., Ding, Y., Oh, H., Busch, E. F., Kaugars, K., Flynn, S., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-017-0003-3 · Cited by 38
Self-citationAnxiety control by astrocytes in the lateral habenula
Tan, W., Ikoma, Y., Takahashi, Y., Konno, A., Hirai, H., Hirase, H., & Matsui, K. (2024) · Neuroscience Research · doi:10.1016/j.neures.2024.01.006 · Cited by 20
Early estradiol exposure masculinizes disease‐relevant behaviors in female mice
Seiffe, A., Ramirez, M. F., Barrios, C. D., Albarrán, M. M., & Depino, A. M. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15130 · Cited by 11
A precision medicine approach to pharmacological adjuncts to extinction: A call to broaden research
King, G., Baker, K. D., Bisby, M. A., Chan, D., Cowan, C. S. M., Stylianakis, A. A., Zimmermann, K. S., & Richardson, R. (2019) · Psychopharmacology · doi:10.1007/s00213-018-4999-0 · Cited by 6
Metadata
- Authors
- Griebel, G., & Holmes, A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2013-08-30
- Volume
- 12
- Issue
- 9
- Pages
- 667-687
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1974420087
- Cited by
- 414
- References
- 284
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.